ERR2208898
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.400
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- HEDGEHOG_SIGNALING+0.300
- NOTCH_SIGNALING+0.300
- E2F_TARGETS+0.200
- MYC_TARGETS_V2+0.200
- APICAL_JUNCTION+0.100
- DNA_REPAIR+0.100
- G2M_CHECKPOINT+0.100
Top 10 suppressed
- HEME_METABOLISM-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- PROTEIN_SECRETION-0.400
- ALLOGRAFT_REJECTION-0.300
- COMPLEMENT-0.300
- FATTY_ACID_METABOLISM-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- ADIPOGENESIS-0.200
- ANDROGEN_RESPONSE-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR975559 | — | — | 0.882 |
| 2 | TCGA-AR-A2LR-01A-12R-A18M-07 | — | E | 0.798 |
| 3 | BS_NB42PWZN | EPN | Supratentorial EPN | 0.790 |
| 4 | TCGA-AN-A0FX-01A-11R-A034-07 | — | E | 0.788 |
| 5 | BS_SD8YBRBR | high-grade glioma | — | 0.769 |
| 6 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.764 |
| 7 | TCGA-AC-A5XU-01A-11R-A28M-07 | — | B | 0.758 |
| 8 | TCGA-AC-A7VC-01A-11R-A352-07 | — | A | 0.756 |
| 9 | SRR8613760 | — | E | 0.755 |
| 10 | SJEPD001544_D1.RNA-Seq | EPN | Supratentorial EPN | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |